Chairman of the Supervisory Board
Mr. Mareel is a seasoned executive in the healthcare industry with significant strategic, operational, and change management experience in senior leadership roles and an in-depth understanding of the global healthcare market. He has held executive leadership positions of increasing responsibility at medium and large international companies. Mr. Mareel last served as Chief Executive Officer (CEO) of Synthon, a privately held, specialty pharmaceutical company. He was leading the organization from a European based generics company to an international specialty pharma company focused on multiple sclerosis and oncology.
During his tenure at Synthon he developed and executed a globally integrated growth strategy that leveraged the company’s product portfolio and R&D capabilities while introducing a more disciplined approach to the operational and commercial side of the business and secured the financing for the company’s long-term growth strategy.Previously, he served as President of International and Member of the Executive Leadership Team at Cardinal Health, a US-based global healthcare company providing medical products, technology and support services. Prior to joining Cardinal Health, he was an Executive Board member at Royal Numico, where he led the consolidation and launch of the company’s global clinical nutrition business and served as its first President. He began his career in healthcare at Abbott Diagnostics and Becton Dickinson, where he held leadership positions of increasing responsibility, ultimately being named Worldwide VP and General Manager of Becton Dickinson’s Immunocytometry business based in San Jose, CA, USA.
Investment manager at LRM
Katleen Vandersmissen joined Limburgse Reconversie Maatschappij (LRM) as an investment manager in 2013. After working for three years in the Platform Sustainable Societies (Recycling, Materials and AgTech), she is now responsible for investments within the Platform Health & Care. She is a board member of several portfolio companies such as EpiGaN and Bedal. Before LRM, she worked as a consultant for McKinsey & Co. and held several positions in Umicore in R&D and Investor Relations. She graduated summa cum laude from the University of Leuven in Chemistry and obtained a PhD in science from the same university. Later she obtained a MBA in Corporate Finance and a post graduate in Corporate Law.
LRM is a regional investment company and has 350 Mio € under management. Venture capital investments are clustered in five domains; Sustainable Societies, Health&Care, Technology&Services, Space&Experience and Smart Manufacturing.
CEO and co-founder of Cardiogenx a company basedin Rotterdam, NL
Dharminder Chahal is CEO and co-founder of Cardiogenx a company based in Rotterdam, NL, developing novel therapeutics and early diagnostic tests for cardiovascular diseases. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Mr. Chahal has built an extensive network in the life science industry and a strong track record in direct involvement of complex corporate transactions including the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of Devgen to Syngenta and the sale of Octoplus to Dr. Reddy’s.
As a board member or advisor he has been and still is active for several European companies in the field of life sciences. At present, Mr. Chahal is a supervisory board member of BioInvent, Sweden, an advisory board member of Biogeneration Ventures II as well as Gilde Healthcare Funds II and III and observer on the supervisory board of Innate Pharma, France. Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co, Robeco and Van Herk Investments. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).
Willem M. de Vos
Professor of Microbiology Wageningen University, NL; Professor of Human Microbiomics University of Helsinki, FI
Willem M. de Vos (1954) studied Biochemistry and obtained a PhD at Groningen University, partly done at the Max Planck Institute for Molecular Genetics in Berlin. He is 30 years Professor at Wageningen University, holds there the Chair of Microbiology, and serves as Professor of Human Microbiomics at the Medical Faculty of the University of Helsinki. He has supervised over 100 PhD students and with these and other collaborators he published over 700 peer-reviewed publications. He is an inventor of over 40 patents or patent applications and has presently an ISI h-index > 110 (Google Scholar > 135). He is a member of the Netherlands Royal Academy of Arts and Sciences (KNAW), the European Academy of Microbiology, and various international Scientific Advisory Boards.
Professor de Vos has received early career prizes for international PhD and post-doc stays, including EMBO, MPI, FEBS and CEC Fellowships, and various career awards, including the Miles Marschall Rhone-Poulenc International Dairy Science Award, the NWO Spinoza Award, and the Netherlands’ Most Entrepreneurial Scientist Award. He also was elected as TEKES Finland Distinguished Professor, Finland Academy Professor of the Finnish Academy of Sciences, received an Honorary Doctorate in Medicine, and an ERC Advanced Grant. His research aims to understand and exploit microbes using molecular, (meta)genomics and systems approaches. His current interest is focused on the human intestinal tract microbiota and its relation with health and disease.